These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 30174604)

  • 21. Conjugation of Triphenylphosphonium Cation to Hydrophobic Moieties to Prepare Mitochondria-Targeting Nanocarriers.
    Guzman-Villanueva D; Mendiola MR; Nguyen HX; Yambao F; Yu N; Weissig V
    Methods Mol Biol; 2019; 2000():183-189. PubMed ID: 31148015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Triphenylphosphonium-Functionalized Mitochondriotropic Nanocarrier for Efficient Co-Delivery of Doxorubicin and Chloroquine and Enhanced Antineoplastic Activity.
    Panagiotaki KN; Sideratou Z; Vlahopoulos SA; Paravatou-Petsotas M; Zachariadis M; Khoury N; Zoumpourlis V; Tsiourvas D
    Pharmaceuticals (Basel); 2017 Nov; 10(4):. PubMed ID: 29160846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rational design, synthesis and biological evaluation of triphenylphosphonium-ginsenoside conjugates as mitochondria-targeting anti-cancer agents.
    Ma L; Wang X; Li W; Li T; Xiao S; Lu J; Xu J; Zhao Y
    Bioorg Chem; 2020 Oct; 103():104150. PubMed ID: 32942193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of Mitochondrial Cell Death and Reversal of Anticancer Drug Resistance via Nanocarriers Composed of a Triphenylphosphonium Derivative of Tocopheryl Polyethylene Glycol Succinate.
    Singh Y; Viswanadham KKDR; Pawar VK; Meher J; Jajoriya AK; Omer A; Jaiswal S; Dewangan J; Bora HK; Singh P; Rath SK; Lal J; Mishra DP; Chourasia MK
    Mol Pharm; 2019 Sep; 16(9):3744-3759. PubMed ID: 31441308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy.
    Yu H; Li JM; Deng K; Zhou W; Wang CX; Wang Q; Li KH; Zhao HY; Huang SW
    Theranostics; 2019; 9(23):7033-7050. PubMed ID: 31660085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism.
    Pathania D; Millard M; Neamati N
    Adv Drug Deliv Rev; 2009 Nov; 61(14):1250-75. PubMed ID: 19716393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitochondrial Delivery of an Anticancer Drug Via Systemic Administration Using a Mitochondrial Delivery System That Inhibits the Growth of Drug-Resistant Cancer Engrafted on Mice.
    Yamada Y; Munechika R; Satrialdi ; Kubota F; Sato Y; Sakurai Y; Harashima H
    J Pharm Sci; 2020 Aug; 109(8):2493-2500. PubMed ID: 32376272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. pH-activated, mitochondria-targeted, and redox-responsive delivery of paclitaxel nanomicelles to overcome drug resistance and suppress metastasis in lung cancer.
    Wang H; Shi W; Zeng D; Huang Q; Xie J; Wen H; Li J; Yu X; Qin L; Zhou Y
    J Nanobiotechnology; 2021 May; 19(1):152. PubMed ID: 34022909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Mitochondrion-Targeted Antioxidants in Kidney Disease.
    Li X; Ma L; Fu P
    Curr Med Chem; 2021; 28(21):4190-4206. PubMed ID: 33081669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier.
    Yamada Y; Harashima H
    Mitochondrion; 2013 Sep; 13(5):526-32. PubMed ID: 23000575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, Anticancer, and Antibacterial Activity of Betulinic and Betulonic Acid C-28-Triphenylphosphonium Conjugates with Variable Alkyl Linker Length.
    Tsepaeva OV; Nemtarev AV; Salikhova TI; Abdullin TI; Grigor Eva LR; Khozyainova SA; Mironov VF
    Anticancer Agents Med Chem; 2020; 20(3):286-300. PubMed ID: 31660842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autonomous metal-organic framework nanorobots for active mitochondria-targeted cancer therapy.
    Peng X; Tang S; Tang D; Zhou D; Li Y; Chen Q; Wan F; Lukas H; Han H; Zhang X; Gao W; Wu S
    Sci Adv; 2023 Jun; 9(23):eadh1736. PubMed ID: 37294758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted photoresponsive carbazole-coumarin and drug conjugates for efficient combination therapy in leukemia cancer cells.
    Wang BY; Lin YC; Lai YT; Ou JY; Chang WW; Chu CC
    Bioorg Chem; 2020 Jul; 100():103904. PubMed ID: 32413630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitochondrial Dysfunction: Pathophysiology and Mitochondria-Targeted Drug Delivery Approaches.
    Khan T; Waseem R; Zehra Z; Aiman A; Bhardwaj P; Ansari J; Hassan MI; Islam A
    Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted delivery of doxorubicin to mitochondria using mesoporous silica nanoparticle nanocarriers.
    Qu Q; Ma X; Zhao Y
    Nanoscale; 2015 Oct; 7(40):16677-86. PubMed ID: 26400067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Power of mitochondrial drug delivery systems to produce innovative nanomedicines.
    Yamada Y; Satrialdi ; Hibino M; Sasaki D; Abe J; Harashima H
    Adv Drug Deliv Rev; 2020; 154-155():187-209. PubMed ID: 32987095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A small molecule nanodrug consisting of amphiphilic targeting ligand-chemotherapy drug conjugate for targeted cancer therapy.
    Mou Q; Ma Y; Zhu X; Yan D
    J Control Release; 2016 May; 230():34-44. PubMed ID: 27040815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel carbon-nanodots-based theranostic nano-drug delivery system for mitochondria-targeted imaging and glutathione-activated delivering camptothecin.
    Gong X; Wang Z; Zhang L; Dong W; Wang R; Liu Y; Song S; Hu Q; Du F; Shuang S; Dong C
    Colloids Surf B Biointerfaces; 2022 Oct; 218():112712. PubMed ID: 35921692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.